Skip to main content

BioAtla Inc

For the period ended Dec 31, 2023. Filed Mar 26, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 26, 2024

BCAB$1.74-44.7%Stored close · as of Aug 28, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Statements of stockholders’ equity

(in thousands, except share amounts)

Common stock · Class Bcommon stock · Additionalpaid-in · Accumulated · Totalstockholders’
SharesAmountSharesAmountcapitaldeficitequity
Balance at December 31, 202135,799,233$41,492,059$—$397,136$(186,319)$210,821
Issuance of common stock, net of $3,318 of issuance costs9,745,1281——61,681—61,682
Issuance of common stock under equity incentive plans, net of shares withheld for taxes364,141——————
Issuance of common stock for Employee Stock Purchase Plan147,564———289—289
Taxes related to net share settlement of equity awards————(534)—(534)
Conversion of Class B Common Stock280,100—(280,100)————
Stock-based compensation expense————14,563—14,563
Net loss—————(106,482)(106,482)
Balance at December 31, 202246,336,166$51,211,959$—$473,135$(292,801)$180,339
Issuance of common stock under equity incentive plans, net of shares withheld for taxes318,634——————
Issuance of common stock for Employee Stock Purchase Plan165,550———336—336
Issuance of common stock for director compensation45,290———107—107
Taxes related to net share settlement of equity awards————(192)—(192)
Conversion of Class B Common Stock1,211,959—(1,211,959)————
Stock-based compensation expense————13,544—13,544
Net loss—————(123,462)(123,462)
Balance at December 31, 202348,077,599$5—$—$486,930$(416,263)$70,672
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.